NCT04706143 is a clinical trial of COVID-19 Vaccines in COVID-19 Vaccines, sponsored by Assiut University.

Who is sponsoring NCT04706143?

NCT04706143 is sponsored by Assiut University.

What drugs are being tested in NCT04706143?

Interventions in NCT04706143: COVID-19 Vaccines.

What condition does NCT04706143 study?

NCT04706143 studies COVID-19 Vaccines.

Is NCT04706143 still recruiting?

NCT04706143 is currently status unknown. Last updated 14 January 2021.

Last reviewed 2021-01-14 · How we verify

NCT04706143

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunologic Responses to Single and Double Doses of COVID-19 Vaccines in Egyptians

Status unknown Last updated 14 January 2021

What this trial tests

trial testing COVID-19 Vaccines in COVID-19 Vaccines in 100 participants. Status unknown.

Timeline

15 January 2021

Primary endpoint
1 June 2021

1 August 2021

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	15 January 2021
Primary completion	1 June 2021
Estimated completion	1 August 2021

Drugs / interventions tested

COVID-19 Vaccines — full drug profile →

Conditions studied

COVID-19 Vaccines — all drugs for COVID-19 Vaccines →

Sponsor

Assiut University

Who can join

Adults 25 to 65, any sex, with COVID-19 Vaccines. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The recent Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and development of safe, effective vaccines is mandatory to return back to pre pandemic life. Many vaccines have been developed and requested by the authorities after the emergency license issued. The main mechanism of protection is through humoral and cell-mediated immune responses that might reduce the potential for disease development or severity. Cytotoxic T cells clear virus-infected host cells and contribute to control of infection. Preliminary data are now available indicating safty and effecacy of different vaccines . The vaccines were tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV-2 spike protein. The aim of this work is to evaluate the immune responses in adults, aged 25-65 years, up to 8 weeks after vaccination with a single and double doses live inactivated (Sinopharm), mRNA (Pfizer/ Biontech) and viral vector (Oxford/AZ- ChAdOx1 nCoV-19) vaccines. The Th1- response ( interferon-γ and tumor necrosis factor-α cytokine secretion by CD4+ T cells) and antibody production predominantly of IgG1 and IgG3 subclasses as well as CD8+ T cells mono, polyfunctional and cytotoxic phenotypes, will be also measured.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

COVID-19 vaccine access in Africa: Global distribution, vaccine platforms, and challenges ahead.
Massinga Loembé M, Nkengasong JN. · · 2021 · cited 76× · PMID 34260880 · DOI 10.1016/j.immuni.2021.06.017

Verify or expand the search:

Other trials of COVID-19 Vaccines

Trials testing the same drug.

NCT05028257 — Allergy and COVID-19 Vaccines · Phase 3 · completed
NCT05017805 — COVID-19 Vaccines in Patients With Chronic Liver Disease · NA · unknown
NCT04981405 — Real-world Evidence of COVID-19 Vaccines Effectiveness · terminated
NCT05228912 — Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries. · completed

Other recruiting trials for COVID-19 Vaccines

Currently open trials in the same condition.

NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
NCT05556720 — Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Contro · Phase 3 · active not recruiting
NCT05096260 — Getting to Yes, Michigan! (G2YMI) · NA · active not recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04706143 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 14 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04706143.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing